ClinicalTrials.Veeva

Menu

Recurrent AA Amyloidosis After Renal Transplantation

I

Istanbul University

Status

Completed

Conditions

AA Amyloidosis

Study type

Observational

Funder types

Other

Identifiers

NCT02704065
32447/199

Details and patient eligibility

About

End-stage renal disease related to AA amyloidosis is well characterized but there is limited data concerning patient and graft outcomes after renal transplantation. The aim of this study is to evaluate the clinical features of, and risk factors for recurrent AA amyloidosis, as well as the effects of these factors on the ultimate outcome of renal allografts.

Full description

AA amyloidosis is a rare but serious complication of several chronic inflammatory diseases including recurrent hereditary periodic fever syndromes. Although end-stage renal disease related to AA amyloidosis is well characterized, there is limited data concerning patient and graft outcomes after renal transplantation, with most of the findings reported from small series. Recurrence of amyloidosis in the renal allograft might be underdiagnosed, assessing graft and patient outcomes in larger study groups will bring better understanding and new strategies in daily practice.

Enrollment

54 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Renal transplantation recipients whose primary renal disease is AA amyloidosis; patients with allograft biopsy-confirmed AA amyloidosis (for study group) and patients with no clinical or laboratory signs of recurrence in the renal allograft (for control group 1)
  • Renal transplantation recipients whose primary diseases are other than AA amyloidosis (for control group 2)

Exclusion criteria

  • Patients who are unwilling or unable to consent

Trial design

54 participants in 3 patient groups

Recurrent AA amyloidosis
Description:
Renal transplant recipients with biopsy-confirmed AA amyloidosis in the renal allograft
Control group 1
Description:
Renal transplant recipients whose primary diseases are amyloidosis with no clinical or laboratory signs of recurrence in the renal allograft
Control group 2
Description:
Renal transplant recipients whose primary diseases are other than amyloidosis

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems